Nantahala Capital Management, LLC Kintara Therapeutics, Inc. Transaction History

Nantahala Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.14 - $6.8 $67,001 - $3.25 Million	478,579 Added 411.74%	594,813 $64,000
Q2 2022 Aug 15, 2022	SELL	$0.14 - $0.5 $76,586 - $273,522	-547,045 Reduced 82.48%	116,234 $32,000
Q3 2021 Nov 15, 2021	BUY	$0.82 - $2.3 $114,800 - $322,000	140,000 Added 26.75%	663,279 $582,000
Q2 2021 Aug 16, 2021	SELL	$1.26 - $2.4 $478,041 - $910,555	-379,398 Reduced 42.03%	523,279 $1.19 Million
Q1 2021 May 14, 2021	BUY	$1.32 - $2.74 $831,214 - $1.73 Million	629,708 Added 230.69%	902,677 $1.57 Million
Q4 2020 Feb 16, 2021	BUY	$1.26 - $1.72 $343,940 - $469,506	272,969 New	272,969 $349,000

Ticker KTRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,807,296
Market Cap $17.8M
Description
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.